Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L3JC
|
|||
| Former ID |
DNC013937
|
|||
| Drug Name |
FGGFTGARKSARKRANQ
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C79H130N30O22
|
|||
| Canonical SMILES |
CC(C(C(=O)NCC(=O)NC(C)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCCN)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCCN)C(=O)NC(CCCN=C(N)N)C(=O)NC(C)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)C(CC2=CC=CC=C2)N)O
|
|||
| InChI |
1S/C79H130N30O22/c1-41(97-60(115)39-96-75(129)62(44(4)111)109-73(127)54(35-46-20-9-6-10-21-46)100-61(116)38-94-59(114)37-95-66(120)47(82)34-45-18-7-5-8-19-45)63(117)101-51(25-16-32-92-78(87)88)69(123)104-49(23-12-14-30-81)71(125)108-56(40-110)74(128)99-42(2)64(118)102-52(26-17-33-93-79(89)90)70(124)103-48(22-11-13-29-80)68(122)105-50(24-15-31-91-77(85)86)67(121)98-43(3)65(119)107-55(36-58(84)113)72(126)106-53(76(130)131)27-28-57(83)112/h5-10,18-21,41-44,47-56,62,110-111H,11-17,22-40,80-82H2,1-4H3,(H2,83,112)(H2,84,113)(H,94,114)(H,95,120)(H,96,129)(H,97,115)(H,98,121)(H,99,128)(H,100,116)(H,101,117)(H,102,118)(H,103,124)(H,104,123)(H,105,122)(H,106,126)(H,107,119)(H,108,125)(H,109,127)(H,130,131)(H4,85,86,91)(H4,87,88,92)(H4,89,90,93)/t41-,42-,43-,44+,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,62-/m0/s1
|
|||
| InChIKey |
YTLZMPJDUFYROB-YRFUXTPFSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nociceptin receptor (OPRL1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.